Sign In
Buy ALNY
$216.98
-2.22 (-1.01%)
At Close: Aug 10, 2026
Alnylam Eyes Faster Drug Discovery With AI Partnership Worth Up To $2 Billion
11:52am, Thursday, 04'th Jun 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stock is up on Thursday after the company announced a strategic collaboration with Inceptive Nucleics, valued at up to $2 billion.
Alnylam, Inceptive sign up to $2 billion AI drug discovery deal
06:05pm, Wednesday, 03'rd Jun 2026
Alnylam Pharmaceuticals said on Wednesday it has teamed up with artificial-intelligence biotech Inceptive in a deal worth up to $2 billion to use AI to speed up discovery of RNA-based medicines.
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
04:45pm, Wednesday, 03'rd Jun 2026
CAMBRIDGE, Mass. & PALO ALTO, Calif.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc., which builds foundation models
Alnylam Issues 2025 Corporate Responsibility Report
08:30am, Tuesday, 19'th May 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the publication of its 2025 Corporate Responsibility Report. The
Pre-Market Stock Futures: Futures are trading lower on Tuesday as the sell-off in technology stocks carried through to Monday and is headed down that road today. All of the major indices, except the D
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
04:40pm, Wednesday, 13'th May 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build
04:15pm, Wednesday, 13'th May 2026
Alnylam Pharmaceuticals NASDAQ: ALNY Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance despite a slower first-quarter sequential growth rate, pointing
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in pa
Alnylam to Webcast Presentations at Upcoming Investor Conferences
08:00am, Thursday, 07'th May 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
08:30am, Monday, 04'th May 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients wit
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth
01:10pm, Friday, 01'st May 2026
ALNY beats Q1 earnings and revenue estimates as Amvuttra sales surge 187%, driving 96% revenue growth and offsetting declines in collaborator revenue and Onpattro sales.
Alnylam Pharmaceuticals: The RNAi Leader Continues To Grind Through A Quieter Year
12:25pm, Friday, 01'st May 2026
Alnylam Pharmaceuticals remains well-positioned in the TTR amyloidosis market, with a robust franchise and reliable clinical asset generation. Q1 2026 results showed 150% year-over-year TTR franchise
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2026 Earnings Call Transcript
12:51pm, Thursday, 30'th Apr 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2026 Earnings Call Transcript
Alnylam (ALNY) Reports Q1 Earnings: What Key Metrics Have to Say
11:01am, Thursday, 30'th Apr 2026
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street
Alnylam Pharmaceuticals (ALNY) Tops Q1 Earnings and Revenue Estimates
10:26am, Thursday, 30'th Apr 2026
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $1.99 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to a loss of $0.01 per share a year ago.
